ORIC Pharmaceuticals (ORIC) Stock Forecast, Price Target & Predictions
ORIC Stock Forecast
ORIC Pharmaceuticals stock forecast is as follows: an average price target of $17.00 (represents a 98.60% upside from ORIC’s last price of $8.56) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
ORIC Price Target
The average price target for ORIC Pharmaceuticals (ORIC) is $17.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $21.00 to $7.00. This represents a potential 98.60% upside from ORIC's last price of $8.56.
ORIC Analyst Ratings
According to 5 Wall Street analysts, ORIC Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for ORIC stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
ORIC Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 05, 2024 | Bradley Canino | Stifel Nicolaus | $20.00 | $9.48 | 110.97% | 133.64% |
| Mar 21, 2024 | Robert Burns | H.C. Wainwright | $21.00 | $14.59 | 43.93% | 145.33% |
| Mar 12, 2024 | David Nierengarten | Wedbush | $20.00 | $14.63 | 36.71% | 133.64% |
| Mar 12, 2024 | Matthew Biegler | Oppenheimer | $17.00 | $14.32 | 18.72% | 98.60% |
| Apr 05, 2022 | Yigel Nochomovitz | Citigroup | $7.00 | $6.90 | 1.45% | -18.22% |
The latest ORIC Pharmaceuticals stock forecast, released on Sep 05, 2024 by Bradley Canino from Stifel Nicolaus, set a price target of $20.00, which represents a 110.97% increase from the stock price at the time of the forecast ($9.48), and a 133.64% increase from ORIC last price ($8.56).
ORIC Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 4 |
| Avg Price Target | - | $20.00 | $19.50 |
| Last Closing Price | $8.56 | $8.56 | $8.56 |
| Upside/Downside | -100.00% | 133.64% | 127.80% |
In the current month, the average price target of ORIC Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to ORIC Pharmaceuticals's last price of $8.56. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 19, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jul 10, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| May 07, 2024 | Citigroup | Buy | Buy | Hold |
| Mar 21, 2024 | Needham | Buy | Buy | Hold |
| Mar 12, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Mar 23, 2023 | H.C. Wainwright | - | Buy | Upgrade |
| Mar 21, 2023 | Guggenheim | - | Buy | Upgrade |
| Mar 16, 2023 | Oppenheimer | - | Outperform | Upgrade |
| May 16, 2022 | Needham | Buy | Buy | Hold |
ORIC Pharmaceuticals's last stock rating was published by H.C. Wainwright on Sep 19, 2024. The company gave ORIC a "Buy" rating, the same as its previous rate.
ORIC Pharmaceuticals Financial Forecast
ORIC Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
ORIC Pharmaceuticals's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. ORIC's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
ORIC Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict ORIC's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than ORIC Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.
ORIC Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-36.12M | $-36.26M | $-35.98M | $-35.84M | $-35.61M | $-33.73M | $-29.02M |
| High Forecast | $-36.12M | $-36.26M | $-35.98M | $-32.39M | $-34.24M | $-33.73M | $-29.02M |
| Low Forecast | $-36.12M | $-36.26M | $-35.98M | $-36.52M | $-36.98M | $-33.73M | $-29.02M |
| Surprise % | - | - | - | - | - | - | - |
ORIC Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ORIC's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
ORIC Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
ORIC Pharmaceuticals's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to ORIC last annual SG&A of $NaN (undefined).
ORIC Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.51 | $-0.51 | $-0.51 | $-0.51 | $-0.50 | $-0.48 | $-0.41 |
| High Forecast | $-0.51 | $-0.51 | $-0.51 | $-0.46 | $-0.49 | $-0.48 | $-0.41 |
| Low Forecast | $-0.51 | $-0.51 | $-0.51 | $-0.52 | $-0.52 | $-0.48 | $-0.41 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, ORIC Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ORIC previous annual EPS of $NaN (undefined).
ORIC Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PMVP | PMV Pharmaceuticals | $1.56 | $18.00 | 1053.85% | Buy |
| IMRX | Immuneering | $1.80 | $17.50 | 872.22% | Buy |
| ANTX | AN2 Therapeutics | $1.00 | $8.75 | 775.00% | Buy |
| PEPG | PepGen | $4.13 | $29.50 | 614.29% | Buy |
| HOWL | Werewolf Therapeutics | $1.71 | $12.00 | 601.75% | Buy |
| MOLN | Molecular Partners | $5.83 | $29.00 | 397.43% | Buy |
| ANEB | Anebulo Pharmaceuticals | $1.53 | $6.00 | 292.16% | Buy |
| CCCC | C4 Therapeutics | $4.20 | $13.50 | 221.43% | Buy |
| MLYS | Mineralys Therapeutics | $11.40 | $30.00 | 163.16% | Buy |
| CELC | Celcuity | $12.46 | $31.50 | 152.81% | Buy |
| CGEM | Cullinan Oncology | $13.45 | $31.50 | 134.20% | Buy |
| ORIC | ORIC Pharmaceuticals | $8.56 | $17.00 | 98.60% | Buy |
| PHVS | Pharvaris | $20.92 | $39.67 | 89.63% | Buy |
| ELVN | Enliven Therapeutics | $24.90 | $39.50 | 58.63% | Buy |
| EWTX | Edgewise Therapeutics | $30.79 | $45.00 | 46.15% | Buy |